Owkin
Owkin is a Paris-headquartered AI-native biotech building the K Pro agentic AI scientist platform for biopharma R&D, licensed to top pharmaceutical companies on multi-year enterprise contracts.
- Company typePrivate
- Founded2016
- HeadquartersNew York, United States
- Headcount—
- GTM typeB2B
- OfferingSoftware
Owkin firmographics
Firmographics- Name
- Owkin
- Legal name
- Owkin Inc.
- Website
- https://owkin.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Short description
- Owkin is a Paris-headquartered AI-native biotech building the K Pro agentic AI scientist platform for biopharma R&D, licensed to top pharmaceutical companies on multi-year enterprise contracts.
- Ownership category
- akta.pro rank
Owkin industry classification
Industry- Product category
- Biopharma AI Platform
- NAICS
- Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
Keywords
Where Owkin is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
Owkin business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- K Pro Platform Licensing: Owkin licenses its K Pro AI scientist platform to pharmaceutical companies through multi-year agreements. The platform is deployed within customers' own systems, with Owkin overseeing end-to-end construction of agentic AI tools. Pricing is based on multi-year licensing arrangements.
- AI Development Partnerships: Co-development agreements with pharmaceutical companies for bespoke AI agents and solutions. These strategic partnerships involve collaborative development of AI tools tailored to specific drug discovery and development workflows.
- Diagnostic Products: AI-powered precision diagnostics including MSIntuit CRC (CE-IVD marked), RlapsRisk BC, and BRCAura for cancer diagnostics. Products are deployed through distribution partnerships including Roche's navify Digital Pathology platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise platform licensing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Owkin product offering
Product offeringCore offering
Owkin develops and licenses an agentic AI platform (K Pro) that supports biopharmaceutical R&D by analyzing multimodal patient data from a federated network of more than 800 hospitals. The platform combines foundation models, AI agents, and federated learning to inform drug target identification, clinical trial design, biomarker discovery, and patient stratification decisions for pharmaceutical and clinical customers.
Differentiator
Problem solved
Functional benefit
Brands
- Waiv: Diagnostic testing spinout formerly known as Owkin Dx, focused on biomedical analysis services and now operating as an independent company with Owkin holding a minority stake.
Products and services
- K Pro An autonomous AI scientist platform that informs decision-making and generates insights across biopharmaceutical R&D, fusing multimodal patient datasets with biological AI systems to accelerate decision-making from early-stage discovery to clinical development. Delivered as a multi-year license to pharmaceutical companies and deployed within customers' own systems.
- K Navigator An agentic AI software platform for academic biomedical researchers that analyzes multiomic patient data and navigates biomedical literature across 26.5 million articles and 19 major databases.
- Pathology Explorer A specialized AI agent for pan-cancer nuclei detection, segmentation and classification in H&E-stained pathology images. Delivers 23.7% better classification accuracy while using five times fewer parameters, and is available through Anthropic's Claude for Healthcare and Life Sciences platform.
Quantifiable outcome
- 70% reduction in drug target identification time
- +5 more outcomes
Companies that use Owkin
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
Owkin technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature11 records
Owkin partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered core, strategic, major and minor.
- Cleveland Clinic Abu DhabicoreCollaboration to launch 'Aila', world's first clinical AI scientist designed to support real-time clinical decision-making and accelerate medical research using real patient data. Initial deployment focuses on prostate cancer, integrating EHR, pathology reports, and medical imaging.
- SanoficoreFive-year K Pro licensing agreement to co-develop next-generation AI-driven biopharma agents. Builds on €90m collaboration since 2021 focused on oncology target identification expanded to immunology. Owkin oversees end-to-end construction of agentic AI tools deployed through K Pro within Sanofi's systems.
- AstraZenecacoreThree-year K Pro licensing agreement for biopharma AI agents integrated into AstraZeneca's IT infrastructure. Agents provide competitive intelligence capabilities for analyzing pharmaceutical targets, assets, trials, and competitive landscape. Prior collaboration produced BRCAura breast cancer AI solution.
- WaivcoreSpin-out from Owkin's diagnostic division with $33M financing. Waiv develops AI-powered precision diagnostics including RlapsRisk BC, MSIntuit Suite, and BRCAura. Owkin retains minority stake and strategic ties as patient validation ecosystem partner.
- 4baseCarestrategicPrecision oncology research collaboration announced at Global AI Impact Summit 2026, India. Partnership aims to advance inclusive precision oncology research using diverse datasets.
- OmicsBankstrategicPartnership announced at Global AI Impact Summit 2026, India to develop more inclusive biological AI and advance drug discovery using India's healthcare data infrastructure.
- AnthropiccorePathology Explorer AI agent integrated through Anthropic's Claude for Healthcare and Life Sciences platform via Model Context Protocol (MCP). Enables healthcare professionals to utilize advanced pathology analysis capabilities within Claude's platform.
- NVIDIAcoreOngoing collaboration benchmarking state-of-the-art NVIDIA models on rigorous biological reasoning tasks to fuel K Pro development. Partnership to advance foundation model capabilities for digital pathology and multiomics analysis.
- Université Paris-SaclaymajorMoU to integrate Owkin's K Pro Free AI co-pilot into university biomedical research and education. Partnership aims to enhance research efficiency and innovation in healthcare.
- Gustave RoussycorePartnership at Franco-German Digital Sovereignty Summit to build Europe's first pan-European agentic infrastructure for biology. Combines agentic AI systems with biomedical data structuring to accelerate drug development across European institutions.
- Charité Comprehensive Cancer Center (Berlin)corePartnership with Gustave Roussy to build Europe's first pan-European agentic infrastructure for biology at Franco-German Summit on Digital Sovereignty. Initiative positions Europe to lead in AI-native biology.
- EpkincoreAffiliate company sponsoring OKN4395 clinical trial. Part of Owkin group's strategy to build specialized independent businesses.
- IDISBa (Fundación Instituto de Investigación Sanitaria Islas Baleares)majorPartnership to use AI to improve cardiovascular disease outcomes, beginning with hypertrophic cardiomyopathy research. Includes structuring AI-ready database and developing data management strategies.
- MicregenminorMicregen used Owkin K platform to prepare investment round materials and validate research for MRG1061 therapeutic candidate targeting pediatric rare diseases.
- Medical University of Vienna / University Hospital ViennamajorStrategic collaboration to deploy Owkin K AI copilot within Vienna's oncology ecosystem. Initial focus on urologic cancers beginning with advanced bladder cancer, enabling researchers to query multimodal patient data.
- NeoGenomicsmajorPartnership with France Tissue Bank to develop first foundation model exclusively trained on immunohistochemistry (IHC) images for AI-driven ADC diagnostics. Leverages NeoGenomics' dataset of 2.5M+ digitized pathology images.
- Hôpital FochmajorFramework agreement to test and validate AI-identified cancer biomarkers on human tumor samples. Builds on prior bladder cancer project where Foch provided samples for organoid validation of AI discoveries.
- Graeme Bell (CFO)coreAppointment of Graeme Bell as Chief Financial Officer to strengthen financial leadership.
- Absci CorporationmajorStrategic partnership combining Absci's generative AI de novo antibody design with Owkin's predictive AI models optimized through biomedical datasets and patient-derived organoids. Collaboration targets immuno-oncology and other indications including immunology and inflammation.
- MSD (Merck & Co)majorPilot program to evaluate MSIntuit CRC digital pathology diagnostic tool on patient identification for colorectal cancer in European hospitals. Collaboration to assess workflow efficiency, diagnosis speed, and resource utilization.
Scale indicators10 records
Recent moves8 records
Expansion highlights8 records
Owkin competitors and assessment
Company assessmentEmerging players
- BPGbio: AI-driven biopharma company combining patient-derived data with computational biology for drug discovery. Comparable as a smaller competitor working at the intersection of patient data, AI, and pharma partnerships.
- XtalPi: AI and quantum physics-driven drug discovery company serving pharma partners. Comparable as an AI-driven pharma platform with overlapping enterprise sales motion, though with more emphasis on computational chemistry than multimodal patient data.
Direct peers
- Schrödinger: Computational chemistry and AI drug discovery platform serving pharma customers with predictive modeling and collaboration agreements. Directly comparable for AI-driven molecular design and pharma enterprise sales model.
- PathAI: AI-powered digital pathology company serving pharma and diagnostics. Directly comparable for Owkin's Pathology Explorer and federated pathology model work, with overlapping biotech customers and pathology AI products.
- Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology, partnering with major pharma (Bristol Myers Squibb, Eli Lilly). Directly comparable as a platform applying AI to pharma R&D with multi-year enterprise licenses and multimodal patient data integration.
- Exscientia: AI-driven precision medicine and drug discovery company with pharma partnerships. Directly comparable as a competing AI R&D platform with similar enterprise licensing motions and patient-derived data integration.
- Isomorphic Labs: Alphabet-backed AI drug discovery company spun out of DeepMind, partnering with Novartis and Eli Lilly on multi-year deals. Directly comparable as a foundation-model-driven drug discovery platform competing for the same top-10 pharma enterprise relationships.
- Recursion Pharmaceuticals: Publicly listed AI-for-drug-discovery company using foundation models and high-throughput experimental data to discover therapeutics. Directly comparable as a competing AI R&D platform selling multi-program partnerships to large pharma customers.
- Iambic Therapeutics: AI-driven drug discovery company combining foundation models with physics-based simulation for therapeutic design. Comparable as a newer entrant in the AI-for-pharma platform category targeting large-pharma partnerships.
Broad incumbents
- Tempus AI: Large-scale healthcare data and AI platform aggregating multimodal patient data for clinical and research use. Comparable as a broader player operating in adjacent territory—patient data licensing and AI for pharma—though with a wider scope across oncology and clinical care.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Owkin social profiles
Digital presenceOwkin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Owkin leadership team
Management profileNumber of profiles
Profiles3 records
Owkin subsidiaries and ownership
Company hierarchySubsidiaries3 records
Owkin funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Owkin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Owkin
What does Owkin do?
Owkin develops and licenses an agentic AI platform (K Pro) that supports biopharmaceutical R&D by analyzing multimodal patient data from a federated network of more than 800 hospitals. The platform combines foundation models, AI agents, and federated learning to inform drug target identification, clinical trial design, biomarker discovery, and patient stratification decisions for pharmaceutical and clinical customers.
Is Owkin a public or private company?
Owkin is a private company. It is classified as venture growth investor backed and is currently operating.
When was Owkin founded?
Owkin was founded in 2016.
Where is Owkin based?
Owkin is headquartered in New York, United States, in the North America region.
How does Owkin make money?
Three revenue lines are on record. K Pro Platform Licensing is the primary driver. The others are AI Development Partnerships and diagnostic Products.
Who are Owkin's main competitors?
Emerging players on record are BPGbio and XtalPi. Direct peers are Schrödinger, PathAI, Insitro, Exscientia, Isomorphic Labs, Recursion Pharmaceuticals and Iambic Therapeutics. Tempus AI is listed as a broad incumbent.
Does Owkin have an API?
No public API is recorded for Owkin.
What industry is Owkin in?
Owkin's product category is Biopharma AI Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 5132 and its SIC code is 7372.